SCHEMBL2551655

SCHEMBL2551655

COCCn1c(-c2c[nH]c(-c3ccc4scnc4c3)n2)nc2ccc(Cl)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.37
▸ CASR P41180 1/20 0.37
▸ RAB9A P51151 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ DRD2 P14416 1/20 0.35
▸ MAP3K11 Q16584 1/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ GRM5 P41594 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2554816 0.91 KDM4E (0.37) RIPK2CASRRAB9AKMT2AKDM4E
SCHEMBL2552122 0.90 PTGER4 (0.37) CASRRAB9AKDM4ERECQLHSD17B10
SCHEMBL2551037 0.90 PTGER4 (0.39) RIPK2CASRRAB9AMAPTKDM4E
SCHEMBL2555588 0.89 HPGD (0.49) CASRRAB9AKMT2AKDM4ERECQL
SCHEMBL14576227 0.88 KDM4E (0.39) CASRRAB9AMAPTKDM4ERECQL
SCHEMBL12284051 0.87 PTGER4 (0.41) CASRRAB9AKDM4ERECQLHSD17B10
SCHEMBL2550197 0.87 CASR (0.36) CASRRAB9AKDM4ERECQLHSD17B10
SCHEMBL12283704 0.87 PTGER4 (0.49) RAB9ANPC1POLBALOX15MAPK1
Hydrochloric Acid SCHEMBL2552919 0.87 PTGER4 (0.41) CASRRAB9AKDM4ERECQLHSD17B10
SCHEMBL12283818 0.86 NPC1 (0.43) RIPK2RAB9AKMT2AKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 — — EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885CASR 2479/4885RAB9A 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback